SinoMab BioScience Auf den Markt gebrachte Aktien
Was ist das Auf den Markt gebrachte Aktien von SinoMab BioScience?
Auf den Markt gebrachte Aktien von SinoMab BioScience Limited ist 259.218M 25.76%
Was ist die Definition von Auf den Markt gebrachte Aktien?
Der Aktien-Float- Anteil ist der Anteil der Aktien einer Gesellschaft, der sich in der Hand öffentlicher Investoren befindet, im Gegensatz zu den gesperrten Stücken
Shares float represents the portion of shares of a corporation that are in the hands of public investors as opposed to locked-in stock held by promoters, company officers, controlling-interest investors, or government. This number is sometimes seen as a better way of calculating market capitalization because it provides a more accurate reflection of what public investors consider the company to be worth. In this context, the float may refer to all the shares outstanding that can be publicly traded
The float is calculated by subtracting the locked-in shares from outstanding shares. Stocks with smaller floats tend to be more volatile than those with larger floats. In general, the large holdings of founding shareholders, corporate cross-holdings, and government holdings in partially privatized companies are excluded when calculating the size of a public float.
Auf den Markt gebrachte Aktien von Unternehmen in Health Care Sektor auf HKSE im Vergleich zu SinoMab BioScience
Was macht SinoMab BioScience?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Unternehmen mit auf den markt gebrachte aktien ähnlich SinoMab BioScience
- NXP Semiconductors N.V hat Auf den Markt gebrachte Aktien von 258.694M 87.54%
- Bortex Global hat Auf den Markt gebrachte Aktien von 258.720M 51.74%
- Wing Chi hat Auf den Markt gebrachte Aktien von 258.751M 27.71%
- Luzheng Futures hat Auf den Markt gebrachte Aktien von 258.811M 93.40%
- Kinnevik AB hat Auf den Markt gebrachte Aktien von 258.831M 107.08%
- The Lakshmi Vilas Bank hat Auf den Markt gebrachte Aktien von 258.892M 76.89%
- SinoMab BioScience hat Auf den Markt gebrachte Aktien von 259.218M 25.76%
- Klondike Silver hat Auf den Markt gebrachte Aktien von 259.330M 98.92%
- Lucero hat Auf den Markt gebrachte Aktien von 259.334M 39.15%
- Canadian Overseas Petroleum hat Auf den Markt gebrachte Aktien von 259.371M 157.89%
- Lapco hat Auf den Markt gebrachte Aktien von 259.400M 64.85%
- Organto Foods hat Auf den Markt gebrachte Aktien von 259.421M 93.52%
- JiaChen hat Auf den Markt gebrachte Aktien von 259.440M 25.94%